Head to head
Cencora vs McKesson
Side-by-side on the measures that matter, with a plain-English read. Full detail: COR · MCK
COR
Cencora
317.25+0.28%
1-year price shape — +4% over the period
Quant Rating C · 45/100
vs
MCK
McKesson
910.33-1.23%
1-year price shape — +22% over the period
Quant Rating C · 65/100
1-year performance, rebased to 100
McKesson edges it on the scoreable measures. McKesson has the highest Quant Rating (65); McKesson has done best over the past year (+22%); McKesson earns the most per share.
| COR | MCK | |
|---|---|---|
| Snapshot | ||
| Sector | Medical Distribution | Medical Distribution |
| Last price | 317.25 | 910.33 |
| Change today | +0.28% | -1.23% |
| 1-year return | +3.5% | +21.8% |
| Market cap | $60.54B | $106.14B |
| 52-week range | 243.78 – 375.33 | 722.11 – 996.84 |
| Valuation | ||
| P/E (TTM) | 23.55 | 24.31 |
| P/E percentile, own 5-yr range | 46th | 45th |
| P/B | 19.84 | -25.03 |
| Dividend yield | 0.74% | 0.36% |
| Profitability & growth | ||
| EPS (TTM) | 7.96 | 38.55 |
| Net profit (TTM) | $1.52B | $4.49B |
| Revenue (TTM) | $332.77B | $410.98B |
| Revenue growth (YoY) | +5.1% | +7.7% |
| Gross margin | 4.0% | 3.6% |
| Operating margin | 1.4% | 1.7% |
| Net margin | 0.8% | 1.1% |
| Free cash flow (TTM) | $4.06B | $6.15B |
| Ownership & sentiment | ||
| Institutional ownership | 102.7% | 92.0% |
| Insider activity (12mo) | 30 buy / 18 sell | 23 buy / 25 sell |
| Short interest (% of float) | 2.3% | 2.5% |
| Analyst consensus | 75% buy / 25% hold (12) | 83% buy / 17% hold (12) |
| Analyst price target | $373 (+18%) | $1,001 (+10%) |
| StockVane view | ||
| StockVane Quant Rating | C (45) | C (65) |
| Company | ||
| Employees | 51,000 | 43,000 |
| Founded | 1947 | 1833 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.